Identiv, Inc. Files Amendment to 2023 Annual Report

TL;DR

<b>Identiv, Inc. has filed an amendment to its 2023 annual report on Form 10-K.</b>

AI Summary

Identiv, Inc. (INVE) filed a Amended Annual Report (10-K/A) with the SEC on April 29, 2024. Identiv, Inc. filed an amendment (10-K/A) to its annual report for the fiscal year ended December 31, 2023. The filing was made on April 29, 2024. The company's common stock trades on The Nasdaq Stock Market LLC under the symbol INVE. Identiv, Inc. is incorporated in Delaware and has its principal executive offices in Fremont, California. The filing is an amendment to the previous 10-K filing.

Why It Matters

For investors and stakeholders tracking Identiv, Inc., this filing contains several important signals. This amendment indicates potential updates or corrections to the previously filed annual financial and operational disclosures for the fiscal year 2023. Investors and stakeholders should review the amended filing for any revised information that may impact their understanding of the company's performance and financial position.

Risk Assessment

Risk Level: low — Identiv, Inc. shows low risk based on this filing. The risk is low as this is an amendment to a standard annual report, typically for clarification or minor corrections, rather than a signal of significant new negative information.

Analyst Insight

Review the specific changes within the 10-K/A filing to understand any updated disclosures regarding Identiv, Inc.'s financial performance or operational status for the fiscal year 2023.

Key Numbers

• 2023-12-31 — Fiscal Year End (Identiv, Inc.)
• 2024-04-29 — Filing Date (Form 10-K/A)
• 0-29440 — Commission File Number (Identiv, Inc.)
• 77-0444317 — IRS Employer Identification Number (Identiv, Inc.)

Key Players & Entities

• Identiv, Inc. (company) — Registrant
• INVE (company) — Trading Symbol
• The Nasdaq Stock Market LLC (company) — Exchange
• Delaware (company) — State of Incorporation
• Fremont (company) — City
• 2023-12-31 (date) — Fiscal Year End
• 2024-04-29 (date) — Filing Date

FAQ

Industry Context

Identiv, Inc. operates in the technology sector, specifically focusing on identity verification and secure access solutions.

Regulatory Implications

The filing is made under the Securities Exchange Act of 1934, requiring public companies to submit regular financial and operational disclosures to the SEC.

What Investors Should Do

1. Analyze the specific amendments made in the 10-K/A filing for any material changes to previously reported information.
2. Verify the accuracy and completeness of Identiv, Inc.'s financial statements and disclosures for the fiscal year 2023.
3. Monitor future filings for any further updates or clarifications related to this amendment.

Key Dates

• 2023-12-31: Fiscal Year End — Reporting period for the annual report.
• 2024-04-29: Filing Date — Date the amendment to the 10-K was filed.

Year-Over-Year Comparison

This filing is an amendment (10-K/A) to the previously submitted annual report for the fiscal year ended December 31, 2023.

Key Financial Figures

• $0.001 — nge on which registered Common Stock, $0.001 par value per share INVE The Nasdaq
• $125,000 — an annual retainer per board year of $125,000, except for the Chairman of the Board o
• $175,000 — igible to receive an annual retainer of $175,000; and an additional annual retainer pe
• $5,000 — ional annual retainer per board year of $5,000 for service on each committee of the Bo
• $20,000 — le to receive an additional retainer of $20,000, and the chair of each of the Compensat
• $10,000 — le to receive an additional retainer of $10,000 for each board year, respectively. Un

Filing Documents

• d813239d10ka.htm (10-K/A) — 360KB
• d813239dex311.htm (EX-31.1) — 4KB
• d813239dex312.htm (EX-31.2) — 4KB
• g813239dsp004a.jpg (GRAPHIC) — 62KB
• g813239dsp004b.jpg (GRAPHIC) — 63KB
• g813239g10g10.jpg (GRAPHIC) — 20KB
• g813239g11g11.jpg (GRAPHIC) — 19KB
• 0001193125-24-122187.txt (&nbsp;) — 1287KB
• inve-20231231.xsd (EX-101.SCH) — 7KB
• inve-20231231_cal.xml (EX-101.CAL) — 1KB
• inve-20231231_def.xml (EX-101.DEF) — 20KB
• inve-20231231_lab.xml (EX-101.LAB) — 30KB
• inve-20231231_pre.xml (EX-101.PRE) — 22KB
• d813239d10ka_htm.xml (XML) — 71KB

Executive Compensation

Executive Compensation 4 Item 12

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 18 Item 13 Certain Relationships and Related Transactions, and Director Independence 21 Item 14 Principal Accountant Fees and Services 22 PART IV Item 15 Exhibits and Financial Statement Schedule 23

Signatures

Signatures 26 Table of Contents PART III ITEM10. DIRECT ORS , EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE Directors The following provides the names, ages (as of April 20, 2024) and description of the backgrounds of our directors. Name Age Chairman of the Board Audit Committee Compensation Committee Nominating Committee Laura Angelini 60 X Steven Humphreys 62 Gary Kremen 60 X X X Richard E. Kuntz, M.D. 67 X James E. Ousley 78 X X X Laura Angelini has served as a director of the Company since October 2022. Ms. Angelini served as General Manager of the Renal Care Global Business Unit at Baxter International Inc. (NYSE: BAX), a healthcare company, from October 2016 to July 2021. Prior to that, Ms. Angelini served in various roles at Johnson & Johnson (NYSE: JNJ), a healthcare company, from July 1991 to September 2016, including as President of North America and Global Franchise Development of Vision Care from 2013 to 2016, Vice-President of Global Strategic Marketing of Ethicon from 2012 to 2013, and Vice President of Medical Devices & Diagnostics of Eastern Europe from 2010 to 2011. Ms. Angelini currently serves as a member of the board of directors of DCC plc, a sales, marketing and support services group and as a member of the board of trustees of Jacksonville University. Ms. Angelini received a bachelor's degree from University La Sapienza, Rome Italy. Ms. Angelini brings to the Board of Directors substantial knowledge and experience in the healthcare industry, an important aspect of the Company's growth strategy. Ms. Angelini's experience in managing global operations for large, multinational healthcare companies and integrating leading-edge technology into their operational processes makes her a valuable addition to our Board of Directors. Steven Humphreys has served as our Chief Executive Officer since September 2015 and as a director since July 1996. Mr. Humphreys previously served as Chairman of the

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION Compensation Discussion and Analysis This Compensation Discussion and Analysis discusses the material elements of the Company's compensation program and analyzes the compensation decisions made for the executive officers included in the Summary Compensation Table (our "Named Executive Officers") for the year ended December 31, 2023. For 2023, we had two "executive officers" as defined in Exchange Act Rule 3b-7. Our Named Executive Officers for 2023 were our principal executive officer and our principal financial officer: Name Position Steven Humphreys Chief Executive Officer and Director Justin Scarpulla Chief Financial Officer and Secretary Executive Summary Our pay-for-performance philosophy links compensation to the achievement of our operational objectives, long-term performance goals and the enhancement of stockholder value. Our Compensation Practices Benefit our Stockholders We are focused on creating an effective compensation program that successfully aligns our key strategic objectives with the interests of our stockholders. To reinforce this, we have adopted policies and practices that guide our compensation practices as summarized below. WHAT WE DO Pay for Performance | A significant portion of our Chief Executive Officer's compensation is at risk, linked to Company performance and stockholder interests. 100% of our Chief Executive Officer's bonus opportunity for 2023 was tied to Company performance metrics and was paid in Company stock. Entirely Independent Compensation Committee | All of the members of the Compensation Committee are independent directors. Reasonable Change-in-Control Arrangements | The post-employment compensation arrangements for our executive officers, including our Named Executive Officers, provide for amounts and multiples that are within reasonable market norms. Our Chief Executive Officer may become eligible for change in control severance upon the occurrence of both a change in

View Full Filing

View this 10-K/A filing on SEC EDGAR